MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Neurology & Neurotherapy Open Access Journal
ISSN: 2639-2178

Beyond Seizure Control: A New Perspective on Precision Medicine and Comprehensive Care in Epilepsy

Isabelle Smit*

Department of Neurology, Leiden University Medical Center, Leiden University, Netherlands

***Corresponding author:** Isabelle Smit, Department of Neurology, Leiden University Medical Center, Leiden University, Netherlands

Perspective

Volume 11 Issue 1

Received Date: February 26, 2026

Published Date: March 19, 2026

Abstract

Epilepsy is one of the most prevalent neurological disorders, affecting more than 50 million people worldwide and imposing substantial medical, psychological, and socioeconomic burdens. Although remarkable advances in antiseizure medications, neuroimaging, genetics, and neurosurgical techniques have improved seizure management, nearly one-third of patients continue to experience drug-resistant epilepsy. Moreover, clinical care has traditionally emphasized seizure reduction while often overlooking cognitive impairment, psychiatric comorbidities, quality of life, and social participation. Emerging innovations in precision medicine, artificial intelligence (AI), wearable technologies, and personalized therapeutics are redefining epilepsy management by enabling earlier diagnosis, individualized treatment selection, and continuous monitoring. This perspective discusses the transition from conventional seizure-focused care toward a comprehensive patient-centered approach that integrates biological, technological, and psychosocial dimensions. Future progress in epilepsy will depend on multidisciplinary collaboration, equitable access to advanced diagnostics, and the implementation of precision neurology to improve both seizure outcomes and long-term well-being.

Keywords: Epilepsy; Precision medicine; Drug-resistant epilepsy; Artificial intelligence; Wearable technology; Personalized therapy; Neurology; Quality of life

Introduction

Epilepsy is a chronic neurological disorder characterized by recurrent unprovoked seizures resulting from abnormal electrical activity within the brain. Despite decades of scientific progress, epilepsy remains a significant global health challenge because of its heterogeneous causes, unpredictable clinical course, and substantial impact on patients and their families. While modern antiseizure medications successfully control seizures in many individuals, approximately one-third of patients continue to experience persistent seizures despite receiving appropriate pharmacological therapy. This treatment gap highlights the need to rethink traditional approaches to epilepsy management [1,2].

Historically, successful treatment has been defined primarily by seizure freedom. Although seizure control remains the cornerstone of therapy, epilepsy affects many aspects of an individual's life beyond seizure occurrence. Cognitive dysfunction, anxiety, depression, sleep disturbances, educational limitations, employment challenges, and social stigma frequently contribute more to reduced quality of life than seizure frequency alone. Consequently, epilepsy care should evolve from a disease-centered model toward a

CC BY

comprehensive framework that addresses both neurological and psychosocial needs throughout the patient's lifespan [2].

Moving Toward Precision Medicine in Epilepsy

Recent advances in molecular genetics and neurobiology have transformed our understanding of epilepsy as a diverse group of disorders rather than a single disease. Genetic discoveries have identified numerous pathogenic variants associated with inherited epilepsies, while improved neuroimaging techniques have enhanced the detection of subtle structural abnormalities that were previously undiagnosed. These developments support the emergence of precision medicine, in which therapeutic decisions are guided by the underlying biological mechanisms responsible for an individual's epilepsy [3].

Precision medicine offers the possibility of selecting the most appropriate antiseizure medication, identifying candidates for epilepsy surgery or neuromodulation, and predicting treatment response more accurately than conventional clinical assessment alone. As genomic sequencing becomes increasingly accessible, integrating genetic information into routine neurological practice may improve diagnostic accuracy and facilitate earlier intervention for patients with rare or treatment-resistant epilepsy [4].

Artificial Intelligence and Digital Innovation in Epilepsy Care

Artificial intelligence is rapidly becoming an important component of modern epilepsy research and clinical practice. Machine learning algorithms are capable of analyzing electroencephalographic recordings, neuroimaging data, and clinical information with increasing accuracy, supporting earlier diagnosis and more precise seizure classification. AI-driven predictive models also show promise in identifying individuals at increased risk of seizure recurrence and estimating treatment outcomes.

Simultaneously, wearable technologies and mobile health applications have introduced new opportunities for continuous patient monitoring outside the hospital environment. Smartwatches, wearable electroencephalographic devices, and smartphone-based seizure diaries can provide objective information regarding seizure frequency, sleep patterns, physical activity, and medication adherence. These technologies may strengthen communication between patients and clinicians while enabling more personalized treatment adjustments based on real-world data [5].

Addressing the Invisible Burden of Epilepsy

The consequences of epilepsy extend well beyond recurrent seizures. Many individuals experience cognitive impairment, mood disorders, memory difficulties, and reduced social participation that substantially affect educational achievement, employment opportunities, and interpersonal relationships. Fear of unpredictable seizures often leads to social isolation and diminished self-confidence, while misconceptions surrounding epilepsy continue to contribute to discrimination in many societies.

Recognizing these challenges requires a broader definition of successful epilepsy care. Comprehensive management should include psychological support, cognitive assessment, counseling, educational assistance, and family involvement alongside pharmacological treatment. Such an integrated approach acknowledges that improving quality of life is an equally important therapeutic objective as achieving seizure control.

Future Therapeutic Directions

The future of epilepsy management will likely involve greater integration of pharmacological innovation, neurotechnology, and individualized care. Advances in gene-targeted therapies, antisense oligonucleotides, regenerative medicine, and neuromodulation have created new possibilities for patients with severe or drug-resistant epilepsies. Closed-loop neurostimulation systems capable of detecting abnormal brain activity and delivering responsive electrical stimulation illustrate how technological innovation can improve seizure control while minimizing adverse effects [6].

Equally important is the development of predictive biomarkers that identify treatment response before therapy begins. Combining genetic information, neuroimaging findings, electrophysiological data, and AI-based analytics may eventually allow clinicians to design individualized treatment strategies that maximize effectiveness while reducing unnecessary medication exposure. Continued collaboration between neuroscientists, engineers, clinicians, and data scientists will be essential to translate these emerging discoveries into routine clinical practice.

Conclusion

Epilepsy management is entering a transformative era in which precision medicine, artificial intelligence, digital health technologies, and multidisciplinary care are reshaping traditional clinical practice. While seizure freedom remains a primary therapeutic objective, future neurological care should also prioritize cognitive health, mental well-being,

Copyright© Isabelle Smit.

social participation, and overall quality of life. Achieving these goals will require a patient-centered approach that recognizes the biological diversity of epilepsy while addressing its broader personal and societal consequences. By integrating scientific innovation with holistic clinical care, the next generation of epilepsy management has the potential to substantially improve outcomes for millions of people living with this complex neurological disorder.

References

1. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, et al. (2017) Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 58(4): 522-530.

2. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, et al. (2010) Definition of drug-resistant epilepsy: Consensus proposal by the International League Against Epilepsy. Epilepsia 51(6): 1069-1077.

3. Thijs RD, Surges R, OBrien TJ, Sander JW (2019) Epilepsy in adults. N Engl J Med 381(6): 539-551.

4. Loscher W, Potschka H, Sisodiya SM, Vezzani A (2020) Drug resistance in epilepsy: Clinical impact, potential mechanisms, and new therapeutic approaches. Nat Rev Neurol 16(10): 595-614.

5. Devinsky O, Vezzani A, O'Brien TJ, Jette N, Scheffer IE, et al. (2018) Epilepsy. Nat Rev Dis Primers 4: 18024.

6. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, et al. (2017) ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58(4): 512-521.

Copyright© Isabelle Smit.